Heart failure (HF) is a pervasive and intricate clinical syndrome arising from structural or functional cardiac disorders. These disorders compromise the heart’s ability to adequately fill with or eject blood, thereby failing to meet the body’s metabolic demands. Characterized by a constellation of symptoms, heart failure primarily manifests as dyspnea, fatigue, reduced exercise tolerance, and fluid retention, often clinically observed as pulmonary and peripheral edema.[1] The classification of heart failure, particularly left ventricular dysfunction, is crucial and is often categorized based on left ventricular ejection fraction (LVEF). Heart failure with reduced ejection fraction (HFrEF) is defined by an LVEF of 40% or less, while heart failure with preserved ejection fraction (HFpEF) is characterized by an LVEF greater than 40%.[2] Effective nursing care for patients with heart failure hinges on accurate diagnosis and tailored interventions. Utilizing the NANDA-I framework for nursing diagnosis is essential in structuring and delivering this care. This article delves into the relevant NANDA nursing diagnoses for heart failure, providing a comprehensive guide for healthcare professionals.
Understanding Heart Failure: Clinical Signs, Symptoms, and Pathophysiology
To effectively apply NANDA nursing diagnoses, a robust understanding of heart failure’s clinical presentation and underlying mechanisms is paramount.
Clinical Signs and Symptoms of Heart Failure
Patients with heart failure commonly present with symptoms stemming from two primary physiological disturbances: fluid overload and reduced cardiac output. Fluid overload leads to symptoms such as dyspnea (shortness of breath), orthopnea (difficulty breathing when lying down), edema (swelling, particularly in the lower extremities), pain from hepatic congestion, and abdominal distention due to ascites. Conversely, reduced cardiac output results in fatigue and weakness, especially pronounced during physical exertion.[1]
The symptom presentation can vary based on the acuity of heart failure. Acute or subacute presentations (developing over days to weeks) are typically marked by shortness of breath at rest or during activity, orthopnea, paroxysmal nocturnal dyspnea (sudden nighttime breathlessness), and right upper quadrant discomfort from acute hepatic congestion, indicative of right heart failure. Palpitations, sometimes accompanied by lightheadedness, may occur if the patient develops atrial or ventricular tachyarrhythmias.
Chronic heart failure (symptoms developing over months) may present with a greater emphasis on fatigue, anorexia, abdominal distension, and peripheral edema compared to dyspnea. Anorexia in chronic HF is multifactorial, arising from poor perfusion of the digestive system, bowel edema, and nausea induced by liver congestion.[1]
Characteristic physical findings in heart failure include:
- Pulsus alternans: An arterial pulse characterized by alternating strong and weak beats, despite a regular rhythm, suggesting left ventricular systolic impairment.
- Displaced Apical Impulse: A laterally displaced apical impulse (point of maximal impulse), often beyond the midclavicular line, indicating left ventricular enlargement.
- S3 Gallop: A low-frequency, early diastolic heart sound, considered a key indicator of ventricular dysfunction.
- Peripheral Edema: Swelling in the extremities due to fluid retention.
- Pulmonary Rales (Crackles): Abnormal lung sounds indicating fluid in the alveoli.
The New York Heart Association (NYHA) Functional Classification[3] provides a standardized method to classify the severity of heart failure based on symptoms:
- Class I: Heart disease is present, but no limitation of physical activity. Ordinary physical activity does not cause undue fatigue, dyspnea, or palpitations.
- Class II: Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitations, or dyspnea.
- Class III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitations, or dyspnea.
- Class IV: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest can be present. If any physical activity is undertaken, discomfort increases.
Pathophysiology of Heart Failure
Heart failure is not a disease itself but a syndrome resulting from various underlying conditions that impair the heart’s pumping ability. These conditions can affect the pericardium, myocardium, endocardium, cardiac valves, vasculature, or metabolism. The most frequent causes of systolic dysfunction (HFrEF) include idiopathic dilated cardiomyopathy (DCM), coronary heart disease (ischemic heart disease), hypertension, and valvular heart disease. Diastolic dysfunction (HFpEF) shares similar etiologies, with hypertrophic obstructive cardiomyopathy and restrictive cardiomyopathy also being significant contributors.[1]
The pathophysiology of heart failure is complex and involves several compensatory mechanisms that, while initially beneficial, ultimately contribute to the progression of the syndrome. These mechanisms include:
- Neurohormonal Activation: The renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS) are activated in response to decreased cardiac output. This leads to vasoconstriction, sodium and water retention, and increased heart rate, initially aiming to maintain blood pressure and cardiac output. However, chronic activation leads to detrimental ventricular remodeling and further heart failure progression.
- Ventricular Remodeling: The heart undergoes structural changes in response to injury and hemodynamic stress. This remodeling can be adaptive initially (e.g., ventricular hypertrophy to maintain output), but over time, it becomes maladaptive, leading to chamber dilation, altered shape, and impaired contractility.
- Fluid Retention: Reduced cardiac output and neurohormonal activation cause the kidneys to retain sodium and water, leading to increased blood volume and congestion.
- Impaired Myocardial Contractility and Relaxation: In systolic heart failure, the heart muscle’s ability to contract is weakened. In diastolic heart failure, the ventricle’s ability to relax and fill properly is impaired, often due to increased stiffness of the ventricular wall.
Understanding these pathophysiological processes is crucial for nurses to accurately interpret clinical manifestations and formulate appropriate NANDA nursing diagnoses.
Image alt text: Chest X-ray illustrating cardiomegaly and pulmonary congestion in a patient with congestive heart failure, demonstrating key radiological signs for diagnostic assessment.
NANDA Nursing Diagnoses for Heart Failure
NANDA International (NANDA-I) provides a standardized language for nursing diagnoses, facilitating effective communication and care planning. For patients with heart failure, several NANDA diagnoses are particularly relevant. These diagnoses guide nursing interventions aimed at addressing the patient’s specific needs and improving outcomes. Based on the common clinical manifestations and pathophysiological changes in heart failure, key NANDA nursing diagnoses include:
- Decreased Cardiac Output
- Activity Intolerance
- Excess Fluid Volume
- Risk for Impaired Skin Integrity
- Ineffective Tissue Perfusion
- Ineffective Breathing Pattern
- Impaired Gas Exchange
- Fatigue
- Anxiety
Each of these diagnoses will be explored in detail, outlining their relevance to heart failure and providing a basis for nursing interventions.
Decreased Cardiac Output
Definition: Inadequate blood pumped by the heart to meet the metabolic demands of the body.
Related to Heart Failure: Decreased cardiac output is a primary physiological consequence of heart failure, regardless of the underlying cause or ejection fraction status. Reduced contractility (in HFrEF) or impaired ventricular filling (in HFpEF) directly leads to insufficient blood ejection.
Manifestations in Heart Failure:
- Weak peripheral pulses
- Hypotension or narrow pulse pressure
- Tachycardia
- Fatigue, weakness
- Dizziness, lightheadedness
- Oliguria (decreased urine output)
- Cool, clammy skin
- Chest pain
- Changes in mental status (confusion, restlessness)
Nursing Interventions:
- Monitor vital signs, including heart rate, blood pressure, and peripheral pulses.
- Assess for signs of poor perfusion (skin color, temperature, mental status, urine output).
- Administer medications as prescribed (e.g., inotropes, diuretics, afterload reducers).
- Promote rest and reduce cardiac workload.
- Monitor fluid balance (intake and output, daily weights).
- Elevate legs to promote venous return.
Activity Intolerance
Definition: Insufficient physiological or psychological energy to endure or complete required or desired daily activities.
Related to Heart Failure: Reduced cardiac output and impaired oxygen delivery to tissues result in fatigue and shortness of breath with exertion, limiting the patient’s ability to perform activities.
Manifestations in Heart Failure:
- Dyspnea on exertion
- Fatigue, weakness
- Increased heart rate in response to activity
- Excessive weakness after activity
- Verbal report of fatigue or weakness
Nursing Interventions:
- Assess the patient’s activity tolerance level.
- Plan activities with rest periods.
- Encourage participation in cardiac rehabilitation programs.
- Monitor vital signs before, during, and after activity.
- Gradually increase activity levels as tolerated.
- Educate the patient on energy conservation techniques.
Excess Fluid Volume
Definition: Increased fluid retention and edema.
Related to Heart Failure: Neurohormonal activation and reduced renal perfusion in heart failure lead to sodium and water retention, causing fluid overload.
Manifestations in Heart Failure:
- Peripheral edema (pitting edema in legs, ankles, sacrum)
- Weight gain
- Dyspnea, orthopnea, paroxysmal nocturnal dyspnea
- Jugular venous distention (JVD)
- Pulmonary congestion (rales/crackles)
- Ascites
- Pleural effusion
Nursing Interventions:
- Monitor fluid balance (intake and output, daily weights).
- Assess for edema and JVD.
- Auscultate lung sounds for rales/crackles.
- Administer diuretics as prescribed.
- Restrict sodium and fluid intake as ordered.
- Position patient to promote fluid redistribution (e.g., elevate legs, semi-Fowler’s position for dyspnea).
- Educate patient on fluid and sodium restrictions and self-monitoring.
Risk for Impaired Skin Integrity
Definition: Vulnerable to alteration in epidermis and/or dermis which may compromise health.
Related to Heart Failure: Edema reduces tissue perfusion and makes skin more susceptible to breakdown, particularly in dependent areas like the legs and sacrum. Poor nutritional status, common in advanced heart failure, further compromises skin integrity.
Risk Factors in Heart Failure:
- Edema
- Decreased mobility
- Poor nutritional status
- Reduced tissue perfusion
Nursing Interventions:
- Assess skin regularly, especially over bony prominences and edematous areas.
- Reposition patient frequently.
- Use pressure-relieving devices (e.g., air mattress, heel protectors).
- Maintain skin hygiene and dryness.
- Ensure adequate nutrition and hydration.
- Educate patient and caregivers on skin care and pressure ulcer prevention.
Ineffective Tissue Perfusion
Definition: Decrease in oxygen resulting in the failure to nourish tissues at the capillary level.
Related to Heart Failure: Reduced cardiac output leads to decreased blood flow and oxygen delivery to peripheral tissues.
Manifestations in Heart Failure:
- Cool, pale, or mottled extremities
- Weak or absent peripheral pulses
- Delayed capillary refill
- Pain (e.g., ischemic pain in legs)
- Changes in mental status
- Decreased urine output
Nursing Interventions:
- Assess peripheral circulation (pulses, skin color and temperature, capillary refill).
- Monitor for signs of ischemia (pain, pallor, paresthesia, paralysis, pulselessness).
- Elevate legs to improve arterial blood flow to the feet.
- Avoid constrictive clothing or positions.
- Maintain adequate hydration (unless contraindicated by fluid overload).
- Administer medications to improve cardiac output and peripheral circulation.
Ineffective Breathing Pattern
Definition: Inspiration and/or expiration that does not provide adequate ventilation.
Related to Heart Failure: Pulmonary congestion and edema impair gas exchange and increase the work of breathing.
Manifestations in Heart Failure:
- Dyspnea, orthopnea, paroxysmal nocturnal dyspnea
- Increased respiratory rate
- Use of accessory muscles of respiration
- Adventitious breath sounds (rales/crackles, wheezes)
- Shallow breathing
- Cyanosis (late sign)
Nursing Interventions:
- Monitor respiratory rate, depth, and effort.
- Auscultate lung sounds.
- Position patient to facilitate breathing (e.g., high Fowler’s position, orthopneic position).
- Administer oxygen therapy as ordered.
- Encourage deep breathing and coughing exercises.
- Monitor oxygen saturation.
- Elevate head of bed.
Impaired Gas Exchange
Definition: Excess or deficit in oxygenation and/or carbon dioxide elimination at the alveolar-capillary membrane.
Related to Heart Failure: Pulmonary edema in heart failure impairs the diffusion of oxygen and carbon dioxide across the alveolar-capillary membrane.
Manifestations in Heart Failure:
- Dyspnea
- Cyanosis
- Confusion, restlessness
- Abnormal arterial blood gases (decreased PaO2, increased PaCO2 in severe cases)
- Decreased oxygen saturation
Nursing Interventions:
- Monitor respiratory status and oxygen saturation.
- Administer oxygen therapy as prescribed.
- Position patient to maximize lung expansion.
- Monitor arterial blood gases if indicated.
- Encourage deep breathing and coughing.
- Suction airway if necessary.
Fatigue
Definition: An overwhelming sustained sense of exhaustion and decreased capacity for physical and mental work at usual level.
Related to Heart Failure: Reduced cardiac output and oxygen delivery to tissues contribute to systemic fatigue in heart failure.
Manifestations in Heart Failure:
- Verbal report of fatigue or lack of energy
- Increased physical and emotional exhaustion
- Inability to maintain usual routines
- Need for increased rest
- Decreased activity tolerance
Nursing Interventions:
- Assess the patient’s level of fatigue and its impact on daily life.
- Plan care to minimize energy expenditure.
- Encourage rest periods.
- Assist with activities of daily living as needed.
- Promote adequate nutrition and sleep.
- Educate patient on energy conservation strategies.
- Refer to occupational therapy or physical therapy for tailored strategies.
Anxiety
Definition: Vague uneasy feeling of discomfort or dread accompanied by an autonomic response (the source often nonspecific or unknown to the individual); a feeling of apprehension caused by anticipation of danger.
Related to Heart Failure: The symptoms of heart failure, the chronic nature of the condition, and the uncertainty of prognosis can contribute to significant anxiety. Dyspnea and fear of death can exacerbate anxiety.
Manifestations in Heart Failure:
- Verbalization of feeling anxious, worried, or fearful
- Restlessness, irritability
- Insomnia
- Increased heart rate, respiratory rate
- Diaphoresis
- Trembling
Nursing Interventions:
- Assess the patient’s level of anxiety.
- Provide a calm and reassuring environment.
- Encourage verbalization of feelings and concerns.
- Provide information and education about heart failure and treatment.
- Teach relaxation techniques (e.g., deep breathing, guided imagery).
- Offer emotional support and counseling.
- Consult with mental health professionals if needed.
Lifestyle Modifications and Nursing Interventions
Effective management of heart failure and addressing the NANDA nursing diagnoses require a multifaceted approach, including lifestyle modifications and targeted nursing interventions. Lifestyle adjustments are crucial for managing symptoms and slowing disease progression. Key recommendations include:
- Dietary Sodium Restriction: Limiting sodium intake to 2-3 grams per day helps to reduce fluid retention.
- Fluid Restriction: Restricting daily fluid intake to approximately 2 liters, as advised by healthcare providers, is vital for managing fluid overload.
- Daily Weight Monitoring: Patients should be taught to monitor their weight daily and report significant changes to their healthcare provider, as this can be an early indicator of fluid retention.
- Medication Compliance: Adherence to prescribed medications, including diuretics, ACE inhibitors, beta-blockers, and others, is essential for symptom control and disease management.
- Regular Exercise: Cardiac rehabilitation and tailored exercise programs can improve functional capacity and quality of life.
- Smoking Cessation and Alcohol Moderation: Eliminating smoking and moderating alcohol intake are crucial for overall cardiovascular health.
Nursing interventions are directly linked to the identified NANDA diagnoses. For instance, for “Excess Fluid Volume,” interventions include diuretic administration, fluid and sodium restriction education, and monitoring fluid balance. For “Activity Intolerance,” interventions focus on energy conservation, activity planning, and cardiac rehabilitation referrals. Patient education is a cornerstone of nursing care, empowering patients to actively participate in their management and improve adherence to lifestyle modifications and treatment regimens.
Conclusion
Utilizing NANDA nursing diagnoses is fundamental to providing structured and effective nursing care for patients with heart failure. By accurately identifying patient needs through diagnoses such as Decreased Cardiac Output, Excess Fluid Volume, Activity Intolerance, and others, nurses can develop targeted care plans. These plans encompass crucial interventions, patient education, and lifestyle modifications, all aimed at alleviating symptoms, improving functional status, and enhancing the quality of life for individuals living with heart failure. The NANDA framework not only guides nursing practice but also ensures a standardized and comprehensive approach to heart failure management, ultimately contributing to better patient outcomes.
References
1.Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW., ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 03;145(18):e895-e1032. [PubMed: 35363499]
2.Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78. [PMC free article: PMC4868779] [PubMed: 26935038]
3.CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 04;316(23):1429-35. [PubMed: 2883575]
4.Lind L, Ingelsson M, Sundstrom J, Ärnlöv J. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Heart. 2021 Sep;8(2) [PMC free article: PMC8438838] [PubMed: 34518286]
5.Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019 Nov 19;9(1):17022. [PMC free article: PMC6863880] [PubMed: 31745178]
6.Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circ J. 2021 Oct;51(10):797-836. [PMC free article: PMC8484993] [PubMed: 34327881]
7.Rezkalla SH, Kloner RA. Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics. Trends Cardiovasc Med. 2021 Apr;31(3):163-169. [PMC free article: PMC7965406] [PubMed: 33383171]
8.Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 15;121(7):819-837. [PubMed: 28912185]
9.Shams P, Ahmed I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Cardiac Amyloidosis. [PubMed: 35593829]
10.Brown KN, Pendela VS, Ahmed I, Diaz RR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Restrictive Cardiomyopathy. [PubMed: 30725919]
11.Matta AG, Carrié D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med Sci Monit. 2023 Mar 06;29:e939020. [PMC free article: PMC9999670] [PubMed: 36872594]
12.Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr;39:100990. [PMC free article: PMC8913320] [PubMed: 35281752]
13.Ahmad SA, Brito D, Khalid N, Ibrahim MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Takotsubo Cardiomyopathy. [PubMed: 28613549]
14.DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CSP, Hsich E. Heart Failure Subtypes and Cardiomyopathies in Women. Circ Res. 2022 Feb 18;130(4):436-454. [PMC free article: PMC10361647] [PubMed: 35175847]
15.Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013 Nov 12;62(20):1845-54. [PubMed: 23850914]
16.Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, Piepoli MF. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):46-51. [PMC free article: PMC7691623] [PubMed: 33238736]
17.Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. [PMC free article: PMC10040794] [PubMed: 36993998]
18.Kim DY, Kim SH, Ryu KH. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019 Sep;49(9):808-817. [PMC free article: PMC6713829] [PubMed: 31456374]
19.Anakwue RC, Onwubere BJ, Anisiuba BC, Ikeh VO, Mbah A, Ike SO. Congestive heart failure in subjects with thyrotoxicosis in a black community. Vasc Health Risk Manag. 2010 Aug 09;6:473-7. [PMC free article: PMC2922308] [PubMed: 20730063]
20.Schoenenberger AW, Schoenenberger-Berzins R, der Maur CA, Suter PM, Vergopoulos A, Erne P. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. Clin Res Cardiol. 2012 Mar;101(3):159-64. [PubMed: 22057652]
21.DiNicolantonio JJ, Liu J, O’Keefe JH. Thiamine and Cardiovascular Disease: A Literature Review. Prog Cardiovasc Dis. 2018 May-Jun;61(1):27-32. [PubMed: 29360523]
22.Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016 Aug 02;68(5):473-482. [PubMed: 27470455]
23.Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014 Jul;8(3):308-15. [PMC free article: PMC4160726] [PubMed: 25221635]
24.Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 03;141(9):e139-e596. [PubMed: 31992061]
25.Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A. [PubMed: 8376698]
26.Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 07;135(10):e146-e603. [PMC free article: PMC5408160] [PubMed: 28122885]
27.Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F, Oguz A, Kruger IM, Diaz R, Yusoff K, Mony P, Chifamba J, Yeates K, Kelishadi R, Yusufali A, Khatib R, Rahman O, Zatonska K, Iqbal R, Wei L, Bo H, Rosengren A, Kaur M, Mohan V, Lear SA, Teo KK, Leong D, O’Donnell M, McKee M, Dagenais G. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 07;395(10226):795-808. [PMC free article: PMC8006904] [PubMed: 31492503]
28.Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006 Jan 28;367(9507):356-67. [PubMed: 16443044]
29.Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. [PubMed: 22227365]
30.Ait Mou Y, Bollensdorff C, Cazorla O, Magdi Y, de Tombe PP. Exploring cardiac biophysical properties. Glob Cardiol Sci Pract. 2015;2015:10. [PMC free article: PMC4448074] [PubMed: 26779498]
31.Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. [PMC free article: PMC9553007] [PubMed: 36237903]
32.Prausmüller S, Arfsten H, Spinka G, Freitag C, Bartko PE, Goliasch G, Strunk G, Pavo N, Hülsmann M. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. J Am Heart Assoc. 2020 Jun 02;9(11):e015071. [PMC free article: PMC7428996] [PubMed: 32427034]
33.Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800-810. [PMC free article: PMC8837825] [PubMed: 33004114]
34.Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):245-257. [PMC free article: PMC6899218] [PubMed: 31202759]
35.Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35. [PMC free article: PMC4654630] [PubMed: 26250359]
36.Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 Jul;19(7):821-836. [PMC free article: PMC5734941] [PubMed: 28560717]
37.King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. Am Fam Physician. 2012 Jun 15;85(12):1161-8. [PubMed: 22962896]
38.Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja F, Sabbah HN, Goldstein S. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J. 1999 Dec;138(6 Pt 1):1133-9. [PubMed: 10577445]
39.Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF, Califf RM, Gheorghiade M., OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005 May 17;111(19):2454-60. [PubMed: 15867182]
40.Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73. [PubMed: 22104551]
41.Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, Køber L, Prescott MF, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 Feb;13(2):e006541. [PubMed: 32065760]
42.Hacker M, Hoyer X, Kupzyk S, La Fougere C, Kois J, Stempfle HU, Tiling R, Hahn K, Störk S. Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging. 2006 Jun-Aug;22(3-4):407-16. [PubMed: 16328851]
43.Jain S, Londono FJ, Segers P, Gillebert TC, De Buyzere M, Chirinos JA. MRI Assessment of Diastolic and Systolic Intraventricular Pressure Gradients in Heart Failure. Curr Heart Fail Rep. 2016 Feb;13(1):37-46. [PubMed: 26780916]
44.Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013 Aug 30;113(6):660-75. [PubMed: 23989711]
45.Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA., American Heart Association Get With the Guidelines-Heart Failure Program. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32. [PubMed: 20123668]
46.Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O’Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW., VICTORIA Study Group. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021 Nov 16;10(22):e021094. [PMC free article: PMC8751950] [PubMed: 34743540]
47.Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM., VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. [PubMed: 32222134]
48.Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000 Dec;140(6):840-7. [PubMed: 11099986]
49.Rider I, Sorensen M, Brady WJ, Gottlieb M, Benson S, Koyfman A, Long B. Disposition of acute decompensated heart failure from the emergency department: An evidence-based review. Am J Emerg Med. 2021 Dec;50:459-465. [PubMed: 34500232]
